您的位置: 首页 > 农业专利 > 详情页

Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
专利权人:
Alethia Biotherapeutics Inc.
发明人:
Tremblay, Gilles Bernard,Viau, Elisabeth,Filion, Mario
申请号:
AU2013224591
公开号:
AU2013224591A1
申请日:
2013.02.22
申请国别(地区):
AU
年份:
2014
代理人:
摘要:
Epidermal growth factor receptor (EGFR) expression and phosphorylation is increased in cancer cells treated with anti-clusterin antibodies. Such treatment is also accompanied with the reappearance of an epithelial phenotype of the cancer cell, as determined by an increased E-cadherin expression at the surface of cancer cells. Clusterin inhibitors may thus induce reversal of the epithelial to mesenchymal phenotype and restore sensitivity of cancer cells to EGFR inhibitors. Combinations of a clusterin inhibitor and an EGFR as well as their use in treatment of cancer are thus provided herewith.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充